Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery followed by adjuvant docetaxel and S-1 for patients with large type 3 or type 4 gastric cancer: Short-term outcomes of the phase II OGSG1902 trial

A phase II study of perioperative capecitabine plus oxaliplatin (CapeOx) therapy for advanced gastric cancer with multiple lymph node metastases (OGSG 1701)

Subgroup analyses of the effect of ramucirumab in pretreatment with immune checkpoint inhibitor in RINDBeRG: a randomized clinical trial in third or further-line treatment of gastric cancer

The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus irinotecan with irinotecan in the third or later line treatment beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG Trial).

TRESBIEN (OGSG 2101) Encorafenib, binimetinib and cetuximab for early recurrent Stage II/III BRAF V600E-mutated CRC

Randomized phase II study of docetaxel vs Paclitaxel for patients with advanced or recurrent esophageal cancer who previously received fluoropyrimidine and platinum-based chemotherapy (OGSG1201)

Phase II feasibility study of adjuvant S-1 plus docetaxel repeated for 6 months as adjuvant chemotherapy for Stage III gastric cancer after curative D2 gastrectomy (OGSG 1002)

A phase II study of panitumumab plus irinotecan for metastatic colorectal cancer with wild KRAS exon 2, resistant to fluoropyrimidine, oxaliplatin, and irinotecan in Japanese. Osaka Gastrointestinal cancer chemotherapy Study Group:（OGSG1001）

A randomized phase II factorial design trial of CPT-11 versus PTX versus each combination with S-1 in patients with advanced gastric cancer refractory to S-1: Final results of OGSG0701

Five-year outcome of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for Stage III gastric cancer after curative D2 gastrectomy (OGSG0604)